Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Heiko Konig, MD, Mhairi Copland, MD, Richard Jove, PhD, Tessa L. Holyoake, MD, PhD, Ravi Bhatia, MD

Blood (2007) 110 (11): 2944.

https://doi.org/10.1182/blood.V110.11.2944.2944

Published: 2007

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD

Blood (2006) 108 (11): 739.

https://doi.org/10.1182/blood.V108.11.739.739

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 693.

https://doi.org/10.1182/blood.V106.11.693.693

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 695.

https://doi.org/10.1182/blood.V106.11.695.695

Published: 2005

Journal Articles

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

Mhairi Copland, MD, Nicholas Heaney, MD, Karen Stewart, BSc, Judith Godden, PhD, Graeme Smith, MD, Charles Crawley, MD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 1125.

https://doi.org/10.1182/blood.V106.11.1125.1125

Published: 2005

Journal Articles

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD MRPharmS, Mhairi Copland, MD, Elaine K. Allan, BSc(Hons), Allen C. Eaves, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 2941.

https://doi.org/10.1182/blood.V104.11.2941.2941

Published: 2004

NARROW

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only